GMAB Quote, Financials, Valuation and Earnings

Evaxion AS has a net margin of 27.27% compared to Genmab AS's net margin of -64.14%. Genmab AS's return on equity of 22.23% beat Evaxion AS's return on equity of --.

Genmab AS has a consensus price target of $29.31, signalling upside risk potential of 39.92%. On the other hand Evaxion AS has an analysts' consensus of $13.25 which suggests that it could grow by 438.62%. Given that Evaxion AS has higher upside potential than Genmab AS, analysts believe Evaxion AS is more attractive than Genmab AS.

Genmab AS has a beta of 1.037, which suggesting that the stock is 3.676% more volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Genmab AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab AS pays -- of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend.

Genmab AS quarterly revenues are $715M, which are larger than Evaxion AS quarterly revenues of $3M. Genmab AS's net income of $195M is higher than Evaxion AS's net income of -$1.6M. Notably, Genmab AS's price-to-earnings ratio is 12.46x while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab AS is 4.39x versus 1.63x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.

Galecto has a net margin of 27.27% compared to Genmab AS's net margin of --. Genmab AS's return on equity of 22.23% beat Galecto's return on equity of --.

Genmab AS has a consensus price target of $29.31, signalling upside risk potential of 39.92%. On the other hand Galecto has an analysts' consensus of $6.00 which suggests that it could grow by 95.44%. Given that Galecto has higher upside potential than Genmab AS, analysts believe Galecto is more attractive than Genmab AS.

Genmab AS has a beta of 1.037, which suggesting that the stock is 3.676% more volatile than S&P 500. In comparison Galecto has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Genmab AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Galecto offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab AS pays -- of its earnings as a dividend. Galecto pays out -- of its earnings as a dividend.

Genmab AS quarterly revenues are $715M, which are larger than Galecto quarterly revenues of --. Genmab AS's net income of $195M is higher than Galecto's net income of -$2.5M. Notably, Genmab AS's price-to-earnings ratio is 12.46x while Galecto's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab AS is 4.39x versus -- for Galecto. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 27.27% compared to Genmab AS's net margin of 50.24%. Genmab AS's return on equity of 22.23% beat Johnson & Johnson's return on equity of 30.18%.

Genmab AS has a consensus price target of $29.31, signalling upside risk potential of 39.92%. On the other hand Johnson & Johnson has an analysts' consensus of $169.18 which suggests that it could grow by 9%. Given that Genmab AS has higher upside potential than Johnson & Johnson, analysts believe Genmab AS is more attractive than Johnson & Johnson.

Genmab AS has a beta of 1.037, which suggesting that the stock is 3.676% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.425, suggesting its less volatile than the S&P 500 by 57.471%.

Genmab AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.23% to investors and pays a quarterly dividend of $1.30 per share. Genmab AS pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Genmab AS quarterly revenues are $715M, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Genmab AS's net income of $195M is lower than Johnson & Johnson's net income of $11B. Notably, Genmab AS's price-to-earnings ratio is 12.46x while Johnson & Johnson's PE ratio is 17.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab AS is 4.39x versus 4.21x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of 27.27% compared to Genmab AS's net margin of 37.18%. Genmab AS's return on equity of 22.23% beat Novo Nordisk AS's return on equity of 84.88%.

Genmab AS has a consensus price target of $29.31, signalling upside risk potential of 39.92%. On the other hand Novo Nordisk AS has an analysts' consensus of $89.76 which suggests that it could grow by 25.54%. Given that Genmab AS has higher upside potential than Novo Nordisk AS, analysts believe Genmab AS is more attractive than Novo Nordisk AS.

Genmab AS has a beta of 1.037, which suggesting that the stock is 3.676% more volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.706%.

Genmab AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 2.32% to investors and pays a quarterly dividend of $1.14 per share. Genmab AS pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Genmab AS quarterly revenues are $715M, which are smaller than Novo Nordisk AS quarterly revenues of $11B. Genmab AS's net income of $195M is lower than Novo Nordisk AS's net income of $4.1B. Notably, Genmab AS's price-to-earnings ratio is 12.46x while Novo Nordisk AS's PE ratio is 21.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab AS is 4.39x versus 7.31x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.